The anticancer ability of FGFC1 was investigated in NSCLS and EGFR-mutant NSCLC cells and reported that FGFC1 inhibited cell growth and cancer cell migration by down-regulating the NF-kB signaling pathway via signaling protein expressions such as IL-6, TNF-α, p-IκB, and p-p65. This evidence concerns the gene EGFR and non-small cell lung carcinoma.